is expected to maintain control over the membrane attack complex-mediated intravascular hemolysis. The approval was based on data from the double-blind, placebo-controlled phase 3 ALPHA trial ...

The approval was based on positive results from the Phase III ALPHA trial, which found that Voydeya improved ... in the press release. Hemolysis can be caused my multiple factors, which include the ...

April 01, 2024--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with ...